# Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
Canonical URL: https://biopharmsignal.com/news/LPCN/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2026
Ticker: LPCN
Company: Lipocine Inc.
Source: Lipocine Inc.
Published: 2026-05-07 20:05 EST
Original Source URL: https://ir.lipocine.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-04 12:00 EST — [Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154](https://biopharmsignal.com/news/LPCN/lipocine-inc-to-host-virtual-kol-event-highlighting-unmet-needs-in-postpartum-depression-and-the-clinical-profile-of-lpcn-1154) — Source: Lipocine Inc.
- 2026-05-19 12:00 EST — [Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting](https://biopharmsignal.com/news/LPCN/lipocine-announces-lpcn-1154-phase-3-data-accepted-for-oral-presentation-at-2026-ascp-annual-meeting) — Source: Lipocine Inc.
- 2026-05-18 12:00 EST — [Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase](https://biopharmsignal.com/news/LPCN/lipocine-to-present-at-a-g-p-s-annual-virtual-healthcare-company-showcase) — Source: Lipocine Inc.
- 2026-05-07 20:05 EST — [Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026](https://biopharmsignal.com/news/LPCN/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2026) — Source: Lipocine Inc.
- 2026-04-02 12:00 EST — [Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression](https://biopharmsignal.com/news/LPCN/lipocine-reports-topline-safety-and-efficacy-results-for-lpcn-1154-in-patients-with-postpartum-depression) — Source: Lipocine Inc.
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)